Clinical trials: Recurrent Venous Thromboembolism
Venous Thromboembolism
D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism
Optimal duration of oral anticoagulant therapy in patients with recurrent episodes of venous thromboembolism (VTE) is a matter of debate and recommendations are based on inadequate evidence.
- Trial name
- NCT00428441
- Testing
- Warfarin
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Università degli Studi dell'Insubria
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism
Recurrence of Thromboembolic Venous Disease of Atypical Location (RUSE)
RUSE is a retrospective data-based study designed to assess the frequency, characteristics and phenotype of documented recurrences of thromboembolic venous disease in atypical locations.
- Trial name
- RUSE (NCT06815874)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Deep Vein Thrombosis of Lower Limb, Lower Extremity Deep Venous Thrombosis Recurrent
Optimal Duration of Anticoagulation in Deep Venous Thrombosis
Prospective cohort study aimed at optimizing the duration of anticoagulant treatment in patients at their first episode of proximal deep venous thrombosis (DVT) of the lower extremities, whose pathogenesis is either unknown…
- Trial name
- MORGAGNI (NCT01285661)
- Testing
- Sodium warfarin
- Where
- Italy
- Volunteers
- 584 people
- Sponsor
- University of Padova
Cardiovascular Diseases, Thromboembolism
Risk Factors for Venous Thromboembolism in the Community
To evaluate the trends in the incidence of venous thromboembolism, to determine the risk factors for venous thromboembolism in patients with medical and surgical illness, and to evaluate the efficacy of the anticoagulant therapy…
- Trial name
- NCT00011180
- Where
- United States
- Volunteers
- 385 people
- Sponsor
- Mayo Clinic
Venous Thromboembolism
Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome
Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years. Reduce the risk of recurrence is a serious public health issue.
- Trial name
- NCT02904967
- Testing
- Extra Blood Draw
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Deep Venous Thrombosis, Pulmonary Embolism
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE).
- Trial name
- Highlow (NCT01828697)
- Testing
- Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 1,110 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Venous Thromboembolism, Neoplasms
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Background Patients with cancer and a first deep venous thrombosis of the leg or pulmonary embolism (venous thromboembolism, VTE) are generally treated with low molecular weight heparin (LMWH)injections for 6 months, since this…
- Trial name
- Longheva (NCT01164046)
- Testing
- low molecular weight heparin, vitamin K antagonists
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- University Medical Center Groningen
Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of…
- Trial name
- PADIS TVP (NCT00740493)
- Testing
- warfarin
- Where
- 14 sites in France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism
Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.
Venous thromboembolism (VTE) is a frequent multifactorial and potential life-threatening disease. Once VTE has been diagnosed, anticoagulation should be started and prolonged for at least three to six months in order to reduce…
- Trial name
- DEBRIEF-VTE (NCT04141254)
- Testing
- Debriefing and educative components, Without debriefing and educative components
- Where
- 10 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism
StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study
The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce…
- Trial name
- SAVER (NCT02679664)
- Testing
- Rosuvastatin
- Where
- 6 sites in Canada, Norway
- Volunteers
- 312 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism, Deep Venous Thrombosis
Aspirin for the Prevention of Recurrent Venous Thromboembolism
To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism, Atherosclerosis
- Trial name
- NCT00222677
- Testing
- aspirin
- Where
- 15 sites in Austria, Italy
- Volunteers
- 70 people
- Sponsor
- University Of Perugia
Thromboembolic Disease Recurrent, Deep Vein Thrombosis
Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
Patients with a history of blood clots are at risk of developing additional clots in the future. Doctors use a tool called a clinical decision rule to tell them how likely it is that a patient has a blood clot and if they should…
- Conditions
- Thromboembolic Disease Recurrent, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- PREDICTORS (NCT02297373)
- Where
- 9 sites in Canada, Netherlands and 1 more
- Volunteers
- 744 people
- Sponsor
- Ottawa Hospital Research Institute
Deep Vein Thrombosis, Pulmonary Embolism
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)
To simplify and improve the diagnostic approach to patients with clinically suspected recurrent DVT by determining whether the results of the combination of IPG and d-dimer testing, using a whole blood agglutination assay, can be…
- Trial name
- NCT00182247
- Testing
- venogram
- Where
- 8 sites in Canada, Italy
- Volunteers
- 600 people
- Sponsor
- Hamilton Health Sciences Corporation
Cancer, Venous Thromboembolism
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study
Objective: To prospectively evaluate clinical outcomes during guideline-recommended LMWH dose escalation for recurrent VTE during LMWH or DOAC treatment for cancer-associated thrombosis.
- Conditions
- Cancer, Venous Thromboembolism, Recurrence
- Trial name
- REDUCE (NCT05229471)
- Where
- 9 sites in Italy, Netherlands and 1 more
- Volunteers
- 220 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Breast Cancer, Colorectal Cancer
Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
RATIONALE: Chemotherapy may cause blood clots to form in the thigh, leg, and lung. This study may help doctors understand how often blood clots occur in patients undergoing chemotherapy.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00433602
- Testing
- clinical observation, management of therapy complications, ultrasound imaging
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cardiovascular Diseases, Heart Diseases
Prevention of Recurrent Venous Thromboembolism (PREVENT)
A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Peripheral Vascular Diseases, Thromboembolism
- Trial name
- NCT00000614
- Testing
- warfarin
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rivaroxaban, Cancer-associated Thrombosis
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Rivaroxaban has been developed in the various clinical settings, prevention of venous thromboembolism (VTE)after major orthopedic surgery, prevention of stroke in atrial fibrillation, and in the treatment of acute coronary…
- Conditions
- Rivaroxaban, Cancer-associated Thrombosis, Recurrence, Bleeding
- Trial name
- NCT01989845
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Seoul National University Hospital
Venous Thrombosis, Pulmonary Embolism
Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis
This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep…
- Trial name
- Du Lac (NCT01164540)
- Testing
- Rosuvastatin (AZD4522)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca